US biopharm Esperion will pay $75 million in cash up front and up to $180 million in milestone payments to acquire Corstasis Therapeutics and its Enbumyst bumetanide nasal spray, the companies said. The deal also includes royalties on sales of current and future Corstasis products, including Enbumyst, which was approved by the FDA in September 2025 for the treatment of of edema associated with heart, kidney, and liver disease.
Corstasis CEO Ben Esque commented, “Enbumyst was purpose-built in partnership with the cardiology community to address a clear unmet need. Today’s acquisition validates our team’s vision and approach. We are excited about the future of Enbumyst in Esperion’s hands and its ability to intervene in the patient setting to treat worsening heart failure at home.”
Esperion President and CEO Sheldon Koenig said, “Enbumyst brings meaningful innovation to millions of patients who continue to struggle with the daily burden of diuretic therapy. Enbumyst’s novel intranasal delivery, established regulatory approval, and expanding clinical footprint make it a natural fit for our cardiovascular franchise.”
Read the Esperion and Corstasis press release
